PDS Biotechnology logo
PDS Biotechnology
PDSB | NASDAQ
Chart Builder DCF Calculator
$0.92
+$0.05 (+5.43%)
At close: Nov 16, 2026, 4:00 PM ET
$0.91
-$0.01 (-0.67%)
After-hours: Nov 16, 2026, 7:48 PM ET

PDS Biotechnology Company Profile

Company profile explained

Company Profile

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.

Key Executives

Name Position
Frank K. Bedu-Addo Founder, President, CEO, Interim CFO & Director
Lars Robert Boesgaard Principal Financial & Accounting Officer and Chief Financial Officer
Stephan Toutain Chief Operating Officer
Gregory L. Conn Chief Scientific Officer
Janetta Trochimiuk Controller & Interim Principal Accounting Officer
Kirk V. Shepard Chief Medical Officer
Spencer Brown Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer

Latest SEC Filings

Date Type Title
Oct 21, 2026 4 Filing
Oct 21, 2026 3 Filing
Oct 20, 2026 4 Filing
Oct 20, 2026 4 Filing
Oct 20, 2026 3 Filing
Oct 20, 2026 3 Filing
Oct 21, 2026 8-K Current Report
Oct 20, 2026 8-K Current Report
Oct 14, 2026 S-3 Filing
Oct 06, 2026 8-K Current Report
View All SEC Filings ➞
PDS Biotechnology
PDS Biotechnology logo
Country United States
IPO Date Sep 30, 2015
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Frank K. Bedu-Addo

Contact Details

303A College Road East Princeton, New Jersey 08540 United States

Stock Details

Ticker Symbol PDSB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001472091
CUSIP Number 70465T107
ISIN Number US70465T1079
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.